Abstract 1801
Background
Clinical research is considered as a cross-disciplinary specialty in modern day medicine merging science and clinical arenas to better public health. The rapidly changing clinical research landscape has led to an array of treatments moving towards a precision medicine platform involving complex interventions. Thus, clear processes to conduct and transition research interventions into clinical practice are more important than ever. Theoretically, implementation of novel interventions require clear methods as part of a fit for purpose framework comprising of effective adaptation processes and practice policies. However, from a practical perspective, implementation of new interventions is more complex especially in specialties such as oncology, NM, IR and DR. This is the first study to systematically scope and review implementation frameworks to understand it’s applicability in clinical specialties.
Methods
We searched 17 databases including PubMed, Medline/OvidSP, Science Direct, PROSPERO, PRISMA, PubMed Health, Embase, EBSCOhost, SciELO, TRIP, ProQuest, Academic search complete, Ageline, Cochrane, Web-of-Science and BIOSIS using a comprehensive search strategy to review publications from January 1st1980 to 31stMarch 2019 in English. We selected 20 publications as per the inclusion/exclusion criteria developed under a review protocol registered with PROSPERO (CRDG42019124020).
Results
There were no publications indicating a validated framework or a specific system used to implement complex interventions within oncology, IR, NM and DR. However, there were generalized implementation processes and adaptation models available. Furthermore, validation studies were not conducted against these frameworks to review their applicability and viability in healthcare especially in the UK.
Conclusions
It is evident there is a research implementation gap in healthcare especially in the UK and additional operational research is required to address this issue. Better alignment between academic theories and healthcare practice is also required to enable better implementation of novel interventions.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2162 - Clinical Benefit and Prices of Cancer Drugs in the US and Europe
Presenter: Kerstin Vokinger
Session: Poster Discussion - Public policy
Resources:
Abstract
4743 - Determinants of the Cancer Drug Funding Process in Canada
Presenter: Joanna Gotfrit
Session: Poster Discussion - Public policy
Resources:
Abstract
6081 - Biosimilar Substitution: European Prescriber Perspectives
Presenter: Michael Reilly
Session: Poster Discussion - Public policy
Resources:
Abstract
1218 - Cost avoided in drugs derived from participation in clinical trials in colorectal cancer
Presenter: Luis Sánchez- Rubio Ferrández
Session: Poster Discussion - Public policy
Resources:
Abstract
3453 - Accessibility and Affordability to Trastuzumab for Breast cancer patients: voices of the Global Oncology community from ONCOLLEGE 001 survey – part 2
Presenter: Sara Altuna
Session: Poster Discussion - Public policy
Resources:
Abstract
3302 - Poster Discussion - Public policy - Analysis of 105.000 cancer patients; have they been discussed in oncologic multidisciplinary team meetings? A nationwide population-based study in the Netherlands
Presenter: Janneke Walraven
Session: Poster Discussion - Public policy
Resources:
Abstract
5246 - Reaching sustainable oncology care via the National Cancer Control Program (NCCP)
Presenter: Branko Zakotnik
Session: Poster Discussion - Public policy
Resources:
Abstract
5586 - Changing landscape of clinical cancer trials in Germany
Presenter: Susen Burock
Session: Poster Discussion - Public policy
Resources:
Abstract
5192 - Comparison between phase III randomized clinical trials and their preceeding phase II studies.
Presenter: Ivan Lyra-Gonzalez
Session: Poster Discussion - Public policy
Resources:
Abstract
5811 - Projecting overall survival data for health-economic models in oncology: do maturity levels impact uncertainty?
Presenter: Isabelle Borget
Session: Poster Discussion - Public policy
Resources:
Abstract